Skip to content
  1. Home
  2. Latest news
  3. Chairman and CEO Alex Gorsky profiled by the Financial Times about Johnson & Johnson’s work on a potential COVID-19 vaccine
lede-alex-gorsky-financial-time-3.jpg

Chairman and CEO Alex Gorsky profiled by the Financial Times about Johnson & Johnson’s work on a potential COVID-19 vaccine

The article explores what guided the decision, which is just the latest example of our Chairman and CEO’s people-first approach to leadership at our healthcare company.

Johnson & Johnson scientists are fast at work on a potential vaccine for COVID-19 that our company plans to provide on a not-for-profit basis.

It’s a decision that underscores our company’s deep commitment to its 77-year-old mission statement, known as Our Credo, which states that Johnson & Johnson’s “first responsibility is to the patients, doctors and nurses, to mothers and fathers and all others who use our products and services. In meeting their needs everything we do must be of high quality.”

That commitment permeates the decisions that Gorsky makes both inside and outside our company, especially during this coronavirus pandemic.

In this Financial Times profile, read about the decision to make the vaccine available on a not-for-profit basis, his work to help redefine the purpose of corporations through the U.S. Business Roundtable—and his people-first approach to leading at Johnson & Johnson.

Read the article: Johnson & Johnson Chief Looks to the Greater Good

How Johnson & Johnson Is Responding to the COVID-19 Pandemic

Learn about the innovative ways the company is mobilizing to help combat the global outbreak caused by the novel coronavirus.

More from Johnson & Johnson

What you need to know about Johnson & Johnson’s 2024 fourth-quarter and full-year earnings report

Check out this infographic breakdown of the company’s fourth-quarter and full-year performance, with highlights from its Innovative Medicine and MedTech businesses.

Terra Kremer, Ph.D., is on a mission to create self-sterilizing surgical tools

Since its launch, Johnson & Johnson has focused on helping make surgeries safer. Learn how this analytical microbiologist and her team are continuing in that tradition with a digital app that aims to change the way medical devices are designed and sterilized.

What is lupus?

Up to 5 million people worldwide live with this complex autoimmune condition, which is more prevalent in women and has a greater disease severity in Latin Americans and patients of African ancestry. Learn how Johnson & Johnson is working to innovate treatments for autoimmune diseases.